Research programme: CAR-TREGs - PolTREG
Latest Information Update: 14 Mar 2024
At a glance
- Originator Medical University of Gdansk; PolTREG
- Developer PolTREG
- Class Anti-inflammatories; Antihyperglycaemics; Antirheumatics; Gene therapies; Regulatory T lymphocyte cell therapies
- Mechanism of Action Gene transference; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Inflammatory bowel diseases; Multiple sclerosis; Neurodegenerative disorders; Rheumatoid arthritis; Type 1 diabetes mellitus
Most Recent Events
- 11 Mar 2024 PolTREG plans phase I trial for Multiple sclerosis and Amyotrophic lateral sclerosis in Poland in early 2025
- 21 Feb 2024 PolTREG plans phase II trial for Multiple sclerosis in second half of 2024
- 19 Jan 2024 PolTREG receives patent allowance for Treg cell therapy to treat Type-1 Diabetes in the USA